Novo Nordisk A/S ADR NVO

$38.58 -0.06 (-0.16%)

Valuation

Market cap
172,527,600,000
Revenue TTM
$46,792,290,000
Net income TTM
$15,508,510,000
PE ratio
9.50
Forward PE
10.80
Profit margin
33.14%
Debt to equity
0.63

Trading

Volume
8,722,100
Avg volume
13,490,852
Day's range
$38.26 – $38.85
Shares out
4,465,000,000
Stochastic %K
87%
Beta
0.76
Analysts
Hold
Price target
$46.38

Price

Company profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare b...

Show more

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
45 44 44 88 88
Website
https://www.novonordisk.com
Address
Novo Alle 1, Bagsvaerd, Denmark

Latest news

Stocktwits

Woodmont Oct 13, 1:09 AM
$NVO Let’s hope we see a rotation into companies that actually make money and pay a dividend
0 replies
Woodmont Oct 12, 11:58 PM
$NVO Expect the unexpected, watch them blowout earnings and announce blowout prescription numbers for the Wegovy pill rollout and guide upwards, it can’t get to much worse than it is at this point, we only have $38 more to the downside but unlimited upside, we need a MRNA type move here with the announcement of some unforeseen positive news!!!
0 replies
Pseudominds Oct 12, 8:40 PM
$NVO my estimate is $50 by q3 earning. End the year with $60. Mid 2027 $80. January 2028 $100
2 replies
PUTZ549 Oct 12, 7:53 PM
$NVO think some quiet "no splash" accumulation going on here jmho nfa
1 replies
Mactd83 Oct 12, 6:51 PM
$NVO W
0 replies
Mactd83 Oct 12, 6:49 PM
$NVO be patient..Big W will provide
0 replies
BullBobo Oct 12, 6:47 PM
$NVO Wish I hold this instead - would not have lost in 12% in a day like today.
1 replies
Quantumup Oct 12, 6:42 PM
H.C. Wainwright⬆️ $RYTM's PT to $130 from $105/reit'd Buy after +'g Japanese HO sales2its mkt model/revising near/medium-term operating expense ests $LLY $NVO VKTX GPCR PTN HCW said -- IMCIVREE, a melanocortin-4 receptor (MC4R) agonist which received orphan drug designation by the MHLW in March 2025, is the first therapy approved in Japan to treat acquired HO. Rhythm currently expects to launch IMCIVREE before the end of 2026, pending final pricing determination. Rhythm estimates there are 5,000 to 8,000 people living with acquired HO in Japan. We anticipate that the company should be able to launch the drug in a timely manner before the end of this year and expect list pricing to be disclosed in the coming months, probably at a level between U.S. and European pricing. As a reminder, the Japanese market may initially exhibit gradual uptake due to the requirement for prescriptions to be renewed fortnightly for newly launched drugs, but we expect sales to ramp steadily starting next year.
0 replies